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Abstract
Genetic prion diseases are late onset fatal neurodegenerative disorders linked to pathogenic mutations in the prion protein-
encoding gene, PRNP. The most prevalent of these is the substitution of Glutamate for Lysine at codon 200 (E200K), causing
genetic Creutzfeldt-Jakob disease (gCJD) in several clusters, including Jews of Libyan origin. Investigating the pathogenesis
of genetic CJD, as well as developing prophylactic treatments for young asymptomatic carriers of this and other PrP
mutations, may well depend upon the availability of appropriate animal models in which long term treatments can be
evaluated for efficacy and toxicity. Here we present the first effective mouse model for E200KCJD, which expresses chimeric
mouse/human (TgMHu2M) E199KPrP on both a null and a wt PrP background, as is the case for heterozygous patients and
carriers. Mice from both lines suffered from distinct neurological symptoms as early as 5–6 month of age and deteriorated to
death several months thereafter. Histopathological examination of the brain and spinal cord revealed early gliosis and age-
related intraneuronal deposition of disease-associated PrP similarly to human E200K gCJD. Concomitantly we detected
aggregated, proteinase K resistant, truncated and oxidized PrP forms on immunoblots. Inoculation of brain extracts from
TgMHu2ME199K mice readily induced, the first time for any mutant prion transgenic model, a distinct fatal prion disease in
wt mice. We believe that these mice may serve as an ideal platform for the investigation of the pathogenesis of genetic
prion disease and thus for the monitoring of anti-prion treatments.
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Introduction
Inherited prion diseases, such as gCJD and Gerstmann–
Stra ¨ussler–Scheinker (GSS), are autosomal dominant disorders
linked to mutations in the gene encoding the prion protein (PrP),
denominated PRNP [1], [2]. The largest focus of gCJD was
identified among Libyan Jews carrying a missense mutation in
codon 200 of PRNP (substituting lysine for glutamate, E200K)
[3,4]. This same mutation was also found in other communities
around the world [5].
As of today, therapeutic intervention in human prion diseases
has failed [6] [7]. Indeed, some protocols reduced the rate of
patients’ deterioration for short periods of time [8], but none could
hope to reverse the severe neurological deficits apparent already at
diagnosis. We therefore propose that efforts should be directed
mostly to develop preventive treatments for subjects at risk, as is
the case for asymptomatic carriers of genetic prion diseases.
Candidate anti-prion reagents will need to be tested in transgenic
models mimicking gCJD. Such transgenic mice should succumb
spontaneously to neurological disease in a high attack rate and in a
short time frame, allowing for long term treatments and
measurable delay of onset well within the life span of the animals.
The model mice should also present prion related biochemistry
and pathology, and if possible transmit disease directly to wt
animals, as is the case for humans suffering from gCJD [9] [10].
Indeed, several animal models of genetic prion disease were
generated in the past, thereby demonstrating that late onset and
spontaneous genetic human prion diseases can be reconstructed in
mice [11,12]. While very useful in the study of prion disease
pathogenesis, not all these models presented all the properties
described above.
The first transgenic (Tg) mice imitating human genetic prion
disease carried a P102L-PrP GSS mutation on a mouse
background and succumb spontaneously to prion disease after
about 4–6 months [13]. However these mice transmitted
infectivity only to unique recipients [14,15], and in addition
presented poor PrP pathology. Tg lines mimicking the PrP
insertional mutation [16], the A117V mutation [17], as well as
both the CJD [18] and the FFI D178N [19] mutation presented
prion-like clinical disease with low to marginal disease related PrP.
The FFI D178N mice transmitted disease to mice overexpressing
wtPrP as well as those expressing wtPrP with the 3F4 epitope, and
the recipient mice developed prion-related neuropathology in the
absence of disease related PrP [19]. Two Tg lines mimicking the
E200K PrP mutation, one on a human PrP gene and another on a
mouse PrP gene did not present disease or other prion related
properties [20] [21].
In this work, we describe a transgenic mouse model for E200K
gCJD expressing a chimeric mouse/human PrP [15,22] both on a
wt and a null PrP background, hereby denominated TgMHu2-
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the wt background mimics most gCJD patients, who are
heterozygous for the PrP mutation [2]. Mice from both lines
presented progressive neurodegenerative disease starting from 5 to
6 month of age, deteriorated and died several months thereafter.
Their brains comprise age related pathology characteristic of prion
disease, such as gliosis and accumulated disease related PrP, which
was shown by immunoblots to be resistant to digestion by high
concentrations of proteinase K (PK). Most important, brain
extracts from both lines transmitted prion disease to wt mice. We
believe that these animals will play a significant role in the
investigation of genetic prion disease pathogenesis and most
important, in the development of novel anti-prion prophylactic
treatments.
Results
TgMHu2ME199K mice develop spontaneous progressive
neurological disease
TgMHu2ME199K on both a wt and a PrP ablated background
were constructed (as described in the methods) by inserting an E to
K substitution at position 199 of a chimeric mouse human
(MHu2M) PrP construct. As of today a total of 300 mice were
generated (240 on an ablated background and 60 on a wt
background), and used for the different experiments described in
this manuscript. These include characterization of clinical disease
as well as investigation of kinetic of disease progression. We also
studied pathological and biochemical prion disease properties of
the Tg mice at different time points before and throughout disease
progression and collected samples for expression and transmission
studies.
The most prominent symptom of disease, which appeared in all
Tg MHu2M E199K mice already at 5–6 months of age, is an a-
symmetric hind limbs weakness that develops with time to
paraplegia. This sign was followed by leg clasping and lower body
atrophy. Contrarily, some of the most characteristic clinical signs
of prion symptoms, i.e. plastic tail and tremor were only apparent
in some of the mice. Figure 1 depicts affected mice suffering from
hind limbs plegia, lower body atrophy and leg clasping. While the
mice in the figure are each from a different line (Tg/ko and Tg/
wt), the different signs appear in all sick mice. The clinical
symptoms of the TgMHu2ME199K mice by order of appearance
are described in Table 1. Table 2 demonstrates the score we
constructed out of these clinical symptoms for kinetic analysis of
disease progression. The time point of death (score 5) was
determined when a mouse was too paralyzed to reach food and
water independently (according to local committee ethical
requirements).
To evaluate the kinetics of disease progression in these mice, a
designated group of 62 TgMHu2ME199K/ko and 14 TgMHu2-
ME199K/wt, (half male, and half female) was followed carefully
from birth throughout disease progression to death. Figure 2a
shows the average age of disease onset (score 1) and disease end
point (score 5) in the transgenic mice. Figure 2 b presents the
severity of disease as related to age (each point represent the
average score in groups of 2–8 littermates, which were averaged
together to avoid individual differences), while figure 2 c
demonstrates disease prevalence in these same groups as related
to age. As stated above, our results indicate that all TgMHu2-
ME199K mice demonstrate first disease symptoms between the
ages of 5 to 7 months old. No significant differences were
observed in clinical and kinetic parameters between male and
female mice. Small differences (non significant) in disease
presentation and progression were observed between mice
expressing the chimeric mutant PrP on null as compared to wt
PrP background (figure 2a), however this may result from the
smaller numbers of mice in the TgMHu2ME199K/wt group.
Additional transgenic mice used in time course experiments
showed similar disease parameters.
PrP expression in TgMHu2ME199K mice
We next investigated the levels of PrP expression in the brains of
the TgMHu2ME199K mice. To this effect, mRNA samples
purified from brains of wt and TgMHu2ME199K/ko 6 months
old mice (4 for each group) were subjected to reverse transcriptase
and subsequently to amplification by real time PCR of PrP and
control genes (see methods). Figure 2d shows that while mRNA
levels of PrP were 20 fold higher in the brains of the transgenic
mice as compared to wt mice, the actual levels of the PrP protein,
as tested by immunoblotting of brain homogenates with a PrP
mAb 6H4, were only increased by 2 folds (figures 2e &f). Whether
this discrepancy between the PrP mRNA and protein levels of
mutant PrP in the Tg mice is of biological significance is unknown
at this point.
Neuropathological evaluation of the spontaneous prion
disease in TgMHu2ME199K mice
Four mm thick sections of formalin-fixed, paraffin-embedded
brains and spinal cords of TgMHu2ME199K mice of different
ages and gene array were evaluated for neuropathology and
PrP immunoreactivity with different a PrP antibodies (see
figure 3a for epitope description of all a PrP antibodies used in
this project). Figure 3b depicts the results for 8 months old mice
( a tl e a s t3i ne a c hg r o u p )o ft h ed i f f e r e n tl i n e s( T g M H u 2-
ME199K/ko, TgMHu2ME199K/wt, PrP
0/0 and wt mice).
Figure S1 presents results for TgMHu2ME199K/ko mice at
d i f f e r e n ta g e s( 3i ne a c hg r o u p ) ,w h i c ha r ea l s os u m m a r i z e di n
figure 4. None of the Tg mice brains exhibited inflammatory
infiltrates, demyelination, axonal swellings, or abnormal
neurites, in accordance with classical prion disease–related
pathology [23].
The predominant form of disease related PrP immunoreactiv-
ity in the TgMHu2ME199K mice was an intraneuronal dot-like
and granular immunostaining in widespread distribution but
Author Summary
Inherited prion diseases, such as genetic CJD, are
dominant disorders linked to mutations in the gene
encoding the prion protein, PrP. Since therapeutic
intervention in all types of human prion diseases has
failed, we propose that therapeutic efforts should be
directed mostly to the development of preventive
treatments for subjects incubating prion diseases, as is
the case for asymptomatic carriers of pathogenic PrP
mutations. These subjects will develop disease symptoms
at some point in their adult life; therefore they should be
treated before clinical deterioration. Candidate treatments
will need to be tested for efficacy and safety first in animal
models that mimic most properties of genetic CJD. In this
work, we describe a new transgenic mouse model for
E200K genetic CJD, presenting progressive neurodegener-
ative disease and age related prion disease pathology and
biochemistry, as is the case in the human disease. Brain
extracts from these mice also transmitted prion disease to
wt mice, as shown before for parallel human samples.
We propose that these animals will play a significant role
in the development of novel anti-prion prophylactic
treatments.
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frontal cortex, and in brainstem nuclei. This was detected by the
C-terminally directed aPrP pAb RTC, and less so by aPrP mAb
12F10 (shown for human in Figure S1). Plaque-like or coarse PrP
immunoreactivity was not seen in any of the sick TgMHu2-
ME199K mice. These patterns of immunopositivity, in particular
the intraneuronal staining, is strikingly reminiscent of recently
described human E200K gCJD [24]. In addition to the
intraneuronal PrP detected by RTC, a fine granular immuno-
staining reminiscent of the so-called synaptic immunoreactivity
was observed by immunostaining for a PrP mAb 6H4 (figure 3b
and figure S1). Interestingly, while the intraneuronal PrP
immunoreactivity was prominent in many regions including the
spinal cord, the synaptic type was rather seen in subcortical gray
matter structures (see figure S1 and figure 4 for time course and
summary of pathological results). Both forms of disease-associated
PrP immunodeposits are present in humans affected by E200K
linked gCJD [24], further supporting the similarity between the
human disease and this animal model.
For technical reasons, the pathological examination of hetero-
zygous E200K human patients [24] could not establish whether
the intracellular staining was associated with E200K PrP, wtPrP or
both PrP forms. However, the examination of our TG model,
which allows for the comparison of Tg/ko with Tg/wt, provides a
partial answer to this question. Since there was no apparent
difference between the PrP immunoreactivity of both these lines
with RTC and 6H4 (figure 3), we may conclude that mutant PrP
thus accumulate intraneuronally in all sick Tg mice. To establish
whether also wt PrP in the TgMHu2ME199K/wt mice can
accumulate inside neurons or produce any form of disease related
PrP, we need an antibody that will recognize only this PrP form.
Regretfully, we could not allocate a reagent with exclusive
specificity for wt PrP as opposed to MHu2M PrP that will also
be suitable for pathological studies.
Figure 1. Clinical Characterization of spontaneous disease in TgMHu2ME199K mice. Typical pictures of sick TgMHu2ME199K mice
showing hind limbs plegia, kyphosis and leg clasping.
doi:10.1371/journal.ppat.1002350.g001
Table 1. Clinical signs by order of appearance.
Percentage of affected mice
A-symmetric hind limbs weakness 100%
A-symmetric hind limbs plegia 100%
Abnormal hind limbs posture 100%
Lower body atrophy 100%
Kyphosis 100%
Myoclonic jerks ,10%
Tremor ,20%
Plastic tail Rare (less than 5%)
Blindness Rare (less than 5%)
doi:10.1371/journal.ppat.1002350.t001
Table 2. Score of disease severity by clinical signs.
Hind limbs weakness 1
Hind limbs partial paralysis 2
Full paralysis in one limb 3
Full hind limbs paralysis 4
Death 5
Additional symptoms such as plastic tail (rare) or tremor added one point to the
total score.
doi:10.1371/journal.ppat.1002350.t002
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in mice [25], were observed only focally at the end-stage of disease,
mostly in the frontal cortex and in the basal ganglia (figure S1).
Mild degree of neuronal loss and reactive astrogliosis was observed
already in 3 months old Tg mice in the basal ganglia, thalamus,
and circumscribed areas of the frontal cortex, as well as in the
spinal cord. These alterations became more prominent in later
stages (at 8 months old and at the end point of disease)
concomitantly with the clinical symptoms described above (see
figure S1 and figure 4).
Figure 2. Disease progression in spontaneous disease. a: Average disease onset and death of mice in kinetic studies. b: Aggravation of clinical
score of disease as related to the mice’s age and gender. Groups of TgMHu2ME199K mice (male and female) were scored for clinical signs from birth
to death. Average disease score for each group was plotted against the age elapsed since the mice birth. Closed circles: males, open circles: females.
c: Percentage of sick mice in each age group. Groups of mice (as in fig b) in which the average score was at least 1 were plotted against the age of the
mice. Closed circles: males, open circles: females d: Relative PrP mRNA levels, as determined by quantitative RT-PCR for wt and TgMHu2ME199K/ko
mice. Each bar represents the average of PrP mRNA normalized against controls genes levels (see methods) in 4 male mice. Statistical bars represent
standard error e: Brain homogenates from TgMHu2ME199K/ko, TgMHu2ME199K/wt, PrP ablated, wt C57BL/6 and RML-infected mice were
immunoblotted with a PrP 6H4 mAb f: Relative intensities of the bands as measured by NIH Image J analysis software.
doi:10.1371/journal.ppat.1002350.g002
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disease
As described above, intraneuronal PrP in the TgMHu2-
ME199K mice was visualized mostly with C-terminal aPrP
antibodies, in particular RTC, a polyclonal antibody which
detects the 201–205 PrP epitope [26], suggesting disease related
PrP may accumulate in the Tg mice as an N-terminally truncated
form. To further test this possibility by biochemical methods, as
well as to evaluate other prion like biochemical properties of PrP in
the Tg mice, we used diverse aPrP antibodies (see figure 3a for
specific epitopes) to immunoblot brain homogenates from 8
months old mice from different genetic backgrounds (figure 5a).
These include TgMHu2M E200K mice on both the ablated (lane
1) and wt (lane 2) PrP background, as well as from age matched wt
TgMHu2M (wt chimeric human PRNP transgene mice (lane 3),
which have not developed spontaneous neurological disease
during their life span [15]. As additional controls, we also tested
brain homogenates from normal (lane 4) and RML scrapie
infected (lane 5) mice (also see insert in figure 5 for sample
description). Panel 5a shows that while aPrP mAb IPC1 reacted
preferentially with samples 2, 4, and 5 which express PrP from a
wt mouse allele, mAb 3F4 reacted only with the samples
expressing TgMHu2MPrP, regardless of the presence of the
E200K mutation or of the additional expression of wt PrP.
Contrarily to the antibodies with species selective immunoreac-
tivity (IPC1 and 3F4), mAb 6H4 recognized PrP forms from all
brain samples at comparable levels (see also figure 1c). Last, the C-
terminal RTC antibody detected equally the established PrP
bands in all samples, but in addition recognized some truncated
PrP forms (of about 10 and 20 kDA) in the samples comprising a
TgMHu2ME199K allele. These bands (see arrows for truncated
forms) were absent from samples of both wt mice and TgMHu2M
controls, suggesting they are specific for PrP in the TgMHu2-
ME199K mice.
To learn more about the PrP bands recognized by pAb RTC
in the Tg mice brains, we subjected the samples presented in
panel a to digestion by PNGase, an enzyme which removes N-
linked sugars from proteins [27]. Figure 5b shows that while the
26 KDa band, representing deglycosylated full length PrP was
detected by RTC in all samples, the TgMHu2ME199K samples
presented additional and unique deglycosylated bands (see
arrows), different also in their molecular weight from the
19 Kda band representing deglycosylated PK resistant PrP in
scrapie brains (lane 5).
Figure 3. PrP immunoreactivity in the brains of TgMHu2ME199K mice. a: Epitope mapping of a PrP antibodies used in these experiments.
b: Four mm thick sections of formalin fixed, paraffin embedded brains from 8 months old TgMHu2ME199K on wt and ablated background, as
compared to wt and PrP ablated mice were tested for disease related PrP immunoreactivity in diverse brain regions with both a PrP pAb RTC and a
PrP mAb 6H4. The figure represents at least 3 samples from each group, and depicts intracellular PrP staining with RTC for the sick Tg mice. Scale bar
in the upper left panel indicates 20 mm.
doi:10.1371/journal.ppat.1002350.g003
Figure 4. Summary of Pathology of TgMHu2ME199K mice: time course. This figure summarizes the pathological findings in
TgMHu2ME199K/ko mice of different ages (at least 3 mice for each age group, see Figure S1) a: the score for gliosis/neuronal loss in different
brain areas of the TgMHu2ME199K mice as a function of aging. b: intraneuronal PrP immunoreactivity score in different brain areas as a function of
aging.
doi:10.1371/journal.ppat.1002350.g004
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homogenates from 8 months old mice from 1: TgMHu2ME199K/ko, 2: TgMHu2ME199K/wt, 3: TgMHu2M, 4: wt C57BL/6, and 5: RML infected mice,
were immunoblotted with several a PrP antibodies (See figure 3a for a PrP epitope mapping). Arrows demonstrate truncated PrP forms only present
in brains of TgMHu2ME199K mice. b: Samples as in panel a were treated in the presence or absence of PNGase and immunoblotted with designated
a PrP antibodies. As above truncated PrP forms are demonstrated only in the TgMHu2ME199K mice demonstrated with arrows. c: Samples as in panel
a were extracted with sarkosyl and then centrifuged at 100000 g for 1 h, separated into pellets and supernatants. Otherwise, similar samples
(denominated as total) were digested with 30 ug/ml PK for 30 min at 37uC. All samples were then immunoblotted with the designated anti PrP
antibodies. Arrows demonstrate PK resistant bands in the TgMHu2ME199K samples. d: Samples from TgMHu2ME199K/ko mice at different ages and
controls were digested in the presence or absence of 30 ug/ml PK for 30 min at 37uC and immunoblotted with a PrP pAb RTC. #1: 1 month old;
#2: 3 months old; #3: 7 months old; #4: another 7 months old sample, #5 PrP ablated mouse; #6 wt mouse, #7 RML infected mouse.
doi:10.1371/journal.ppat.1002350.g005
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TgMHu2ME199K mice are aggregated and PK resistant,
properties established as the hallmark of disease related PrP, we
subjected Sarkosyl extracted brain homogenates from sick
TgMHu2ME199K mice and controls (same lane numbering as
above) to centrifugation at 100,000 g. In parallel, similar
homogenate samples were digested with 30 mg/ml PK for
30 minutes at 37uC. The samples generated by these experiments
were immunoblotted with a PrP antibodies 6H4 and RTC.
Figure 5c shows that a significant fraction of the PrP protein
present in the sick mice (lanes 1&2) pelleted under these
conditions, resembling the fraction of aggregated PrP in scrapie
infected mice (lane 5). This was not the case for PrP in the samples
from the control chimeric or from the wt mice (lanes 3&4). As in
the previous panel, immunoblotting of the same samples with pAb
RTC revealed additional lower bands of about 10 to 20 Kda, in
both the pellet and the supernatant. Following digestion of the
homogenates with PK, and consistent with the pathological results
(figure 2); it was again RTC that could detect the PrP bands
resistant to protease digestion.
To establish whether truncated PK resistant PrP in the brains of
TgMHu2ME199K mice are a feature of the mutated PrP chimera
at all ages or represent the onset of disease in older mice, we
looked for their presence in the brains of young and asymptomatic
TgMHu2ME199K mice. Figure 5d shows that PK resistant PrP
was absent at 1 month of age (lane 1), barely present at 3 months
of age (lane 2), but was clearly apparent at 8 months of age (lanes 3
and 4), when animals were severely sick. These results demonstrate
that, consistent with the immunohistochemistry results described
in figure 4, the appearance of PK resistant PrP forms correlate
with age and disease progression, and are not an automatic feature
of mutated PrP.
Oxidation properties of PrP in the spontaneous and the
transmitted disease
We have recently shown that pAb RVC, a polyclonal antibody
generated against reduced 203–214 human/mouse PrP peptides,
could not detect Human PrP
Sc in brains of genetic or sporadic
CJD patients [26]. This and other experiments demonstrated that
Methionine residues (Met) in human PrP
Sc are present in an
oxidized form. This was also the case for Met residues in
recombinant human E200K PrP. To test the oxidation status of
PrP in our sick TgMHu2ME199K mice, we subjected Sarkosyl
extracted brain homogenates from wt and from TgMHu2-
ME199K/ko mice, as well as from mice infected with RML
prions to 10–60% sucrose gradients. Subsequently, the gradient
fractions were immunoblotted with both RTC and RVC a PrP
antibodies. Figure 6 shows how PrP in the TgMHu2ME199K
mice (both full length and truncated) was detected in all the
gradients fractions when the blots were challenged with pAb RTC,
indicating the mutant protein may be present in the brains of these
mice at diverse aggregation states. In contrast, pAb RVC detected
only full length PrP in the lighter fractions, suggesting that
TgMHu2ME199K PrP may be oxidized and aggregated during its
metabolic pathway in the Tg mice, as is also the case for PrP
Sc in
the infected brains. These experiments indicate that most mutant
PrP in the Tg mice is not oxidized immediately upon its
generation, but becomes oxidized concomitantly with its aggrega-
tion during its metabolic pathway.
Transmission of spontaneous disease from
TgMHu2ME199K to wt mice
Brain samples from heterozygous patients carrying the E200K
PrP mutation were shown to transmit prion disease to primates [9]
as well as to both wt and TgMHu2M PrP mice [10,28]. To test if
our mice also produce infectious prions in addition to fatal
spontaneous disease, we inoculated the brain homogenates from
an asymptomatic TgMHu2ME199K/wt mouse, from a sick
TgMHu2ME199K/wt mouse, as well as from a sick TgMHu2-
ME199K/ko to groups of wt (C57Bl/6) mice.
We speculated that the presence of a wt allele in the E199K PrP
Tgs may induce the formation of some levels of wt PrP
Sc, thereby
facilitating transmission of disease to wt mice following their
infection with brains of the Tgs. To this effect, we inoculated the
samples from the heterozygous mice only intraperitoneally (i.p.),
which although resulting in a longer inoculation time is a less
Figure 6. Oxidation of TgMHu2ME199K PrP in Tg mice. PrP
Sc in mice, hamsters and human samples cannot be detected by aPrP RVC,
demonstrating it is oxidized in it helix3 Met residues. To see if this is also the case for all or part of E200K PrP in the Tg mice, brain homogenates from
(wt C57BL/6, TgMHu2ME199K/ko, and scrapie RML), were extracted with sarkosyl and subjected to ultracentrifugation in 10–60% sucrose gradients.
Individual fractions of each of the gradients were immunoblotted respectively with a PrP antibodies RTC and RVC. The figure shows that aggregated
forms of the mutant protein are not recognized by this antibody, as is the case for RML PrP
Sc.
doi:10.1371/journal.ppat.1002350.g006
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TgMHu2ME199K/wt was inoculated both i.c. (intracerebrally)
and i.p., to maximize the possibility of transmission. As control for
the experiment, the brain homogenate of a wt Tg MHu2M mouse
was inoculated i.p. into a C57B/6 group. These mice were shown
previously to remain healthy for more then 640 days [15]. In
addition, a wt C57B/6mouse brain homogenate was inoculated
i.c. to a group of mice in the same room as a general control for
contamination.
All inoculated animals were evaluated twice a week for clinical
signs. Figure 7a shows a typical sick mouse infected with any of the
TgMHu2ME199K brain samples, demonstrating lower body
atrophy and hind limbs weakness, both properties reminiscence
of the spontaneous disease of the donor Tg mice. The transmitted
mice also showed ‘‘tip toe’’ walking, a rare feature described only
in some prion related models [29]. Clinical signs present in other
infectious prion strains, such as kyphosis and plastic tail, were also
observed in these mice, as opposed to the donor Tgs. The
transmitted disease affected the 6 mice of group 9.9 (inoculated
with brain homogenate from a sick TgMHu2ME199K/wt
mouse), 3 out of 5 mice of group 9.3 (inoculated with the brain
extract from an asymptomatic TgMHu2ME199K/wt mouse), 2
out of the 5 mice inoculated i.c. and 1 out of 6 mice inoculated i.p
with a brain extract of a sick TgMHu2ME199K/ko mouse.
Disease signs appeared first in the mice infected i.p. with
TgMHu2ME199K/wt at about 160–180 days and progressed to
their death 2–3 months thereafter (see figure 7c for survival
results). After infection with TgMHu2ME199K/ko, some mice
became sick at 210 days (i.c) and 300 days (i.p.). While disease in
these mice was apparently shorter than in the ones infected with
TgMHu2ME199K/wt brains (2–3 weeks), no conclusions can be
drown from this observation due to the small numbers. None of
the control mice (Tg MHu2M and wt) develop any signs of disease
for more than 400 days.
Our results therefore indicate that, like in human E200K brains
[10,28], infectious prions are spontaneously formed in brains of
TgMHu2ME199K mice. Most important, potential infectivity is
generated in these mice brains before the appearance of clinical
Figure 7. Transmission of TgMHu2ME199K prions to wt mice. a: Picture of a wt C57BL/6 mouse infected with brain homogenates from
TgMHu2ME199K/wt mice showing abnormal hind limb posture. Upper panel shows foot prints of the mice as compared to wt mice, demonstrating
abnormal pattern of walking. b: Survival curves for wt C57BL/6 mice infected i.p with a TgMHu2ME199K/wt sick mouse brain (group 9.9, close square)
or a TgMHu2ME199K/wt asymptomatic mouse brain (group 9.3, open square), as well as i.c (close circles) or i.p (open circles) infected with a
TgMHu2ME199K/ko sick mouse brain, or i.p with the brain homogenate of TgMHu2M mice (close diamond) and i.c with wt brain homogenate (open
triangle). c: Brain homogenates of RML infected and wt mice as well as mice (1&2) infected with TgMHu2ME199K/wt brain homogenate (group 9.3)
immunoblotted in the presence and absence of PK digestion with a PrP pAb RTC. d: Brain homogenates digested in the presence or absence of PK
and immunoblotted with a PrP pAb RTC of the brain samples described in table 3. Upper panel: 2PK, lower Panel: +PK overdeveloped. Compare
sample 1 in figures c and d to appreciate the overdevelopment factor.
doi:10.1371/journal.ppat.1002350.g007
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transmitted disease to some of the wt mice. The levels of infectious
prions may further increase with disease progression, as seen by
the fact that mice infected with the sample from a sick
TgMHu2ME199K/wt mice (group 9.9) succumbed to disease in
a relative short time, as compared to asymptomatic sample 9.3.
Our results also suggest that the wt allele in heterozygous mice
may facilitate the transmission of infectivity to naı ¨ve wt mice, since
transmission from a sick TgMHu2ME199K/ko mice required a
very long incubation time and occurred only occasionally, in
particular after i.p. inoculation. Facilitation of disease transmission
by a wt allele may result from the in-vivo generation of wt PrP
Sc in
the TgMHu2ME199K/wt mice (even if at marginal levels),
concurrently with the quantitative spontaneously generation of
mutant disease related PrP. This may indicate that the ‘‘species
barrier’’ between both forms of PrP may have been abrogated to
some extent in the TgMHu2ME199K/wt mice. It also implies
that while wt PrP has little or no effect on the actual presentation
of spontaneous disease and its progression, low levels of wt PrP
Sc in
these animals may be very central for the further passage of disease
to naı ¨ve wt mice.
PK resistant PrP in the brains of transmitted wt mice
Figure 7c shows an a PrP immunoblot (pAb RTC) of brain
homogenates from individual mice, either infected with scrapie
RML, naı ¨ve C57B/6, or infected with a brain homogenate from
an asymptomatic TgMHu2ME199K/wt mouse, 9.3 (see table 3
for the numbering of samples in figure 7c &d). As can be seen in
the figure, sample 1 (derived from sick wt mouse 224 days post
infection) presents a similar pattern of disease related PrP as in the
RML infected sample, as opposed to, sample 2 (derived from a
healthy wt mouse 413 days post infection) in which no PrP
Sc can
be detected. Figure 7d presents an immunoblots in which
individual PK digested samples from infected mice were
overdeveloped to allow for the detection of low levels of PK
resistant PrP. Consistent with the results in figure 7c, PrP
Sc was not
be detected in the asymptomatic mice from group 9.3. Contrarily,
figure 7d shows that PK resistant PrP forms could be detected in
the brains of a selection of brains from mice that succumbed to
disease, however the levels and pattern of disease related PrP
differed significantly between individual samples (see summary in
Table 3). This was true even for extracts of mice infected with the
same inoculum, and presenting the same symptoms, as was the
case for samples 5–8, which were infected with brain homogenate
of a sick TgMHu2ME199K/wt mouse, and samples 9 and 10,
both infected with a TgMHu2ME199K/ko brain extract. As
opposed to the donor Tg mice, no truncated PrP forms were
observed with this antibody in any of the samples. The different
levels of PrP
Sc in wt mice inoculated with the same prion
homogenate are consistent with results from experiments describ-
ing the transmission of BSE into wt mice [30]. In that case the
presence of PrP
Sc in the direct transmission from cow brains could
be detected only in about 50% of the mice, while fatal disease
presented in all of the animals. PrP
Sc became apparent in all mice
following adaptation of the new strain by additional mice to mice
passages.
Neuropathological evaluation of wt mice infected with
TgMHu2ME199K brains
Sections of formalin-fixed, paraffin-embedded brains of mice
infected with TgMHu2ME199K/wt, TgMHu2ME199K/ko and
RML prions were examined for prion parameters. Figure 8a
presents sections of the frontal cortex. Brains infected with
TgMHu2ME199K samples present minor to moderate spongi-
form changes, distinctly different from the high levels of
spongiform changes apparent in the RML strain [31]. The
infected mice also showed severe astrogliosis and neuronal loss, as
well as prominent diffuse synaptic type disease-related 6H4 PrP
immunoreactivity, similar to the ones seen for the RML sections.
As opposed to the spontaneous disease of TgMHu2ME199K mice
(figure 3), only low levels of RTC related immunostaining were
observed in the infected mice’s brains, as shown in figure 8a for the
sample infected with a TgMHu2ME199K brains. RTC immuno-
staining was not observed in the RML samples.
To test whether RTC related immunostaining can distinguish
better between the RML and TgMHu2ME199K generated prions
at a different experimental setup, we immunostained sections of
TgMHu2ME199K and RML infected mice with RTC following a
less harsh epitope revealing treatment (no formic acid after heating
with citrate). Figure 8b shows that under these conditions, pAb
RTC detected intracellular PrP aggregates in the mice infected
with TgMHu2ME199K, but not in those infected with RML
homogenates. Both brain samples presented a diffused immuno-
reactivity reminiscence of PrP
C. No immunoreactivity of any kind
was observed in brains of PrP ablated mice, indicating that the
positive stain in the infected sample is indeed PrP.
In conclusion, clinical, biochemical and pathological results
presented in this section demonstrate that brains from TgMHu2-
ME199K mice may generate de-novo prions with specific
properties. These prions may readily transmit to wt mice, and
are particularly infectious when in the brains of sick TgMHu2-
ME199K on a wt background. Whether other organs of these
mice, and in particular blood and immune cells, may also transmit
infectivity remains to be established. Results from such experi-
ments may be very important to assess blood safety in the
community.
Discussion
Constructing a clinically relevant mouse model has proven to be
a hard task for most neurodegenerative diseases [32]. The existing
Table 3. Summary of transmission studies.
sample group
PK resistant
PrP
Age of
death (days)
1 Infected with Tg/wt 9.3 (i.p) +++ 224
2 Infected with Tg/wt 9.3 (i.p) 2 Sac at 413
3 Infected with Tg/wt 9.3 (i.p) 2 Sac at 413
4 Infected with Tg/wt 9.3 (i.p) 2 Sac at 413
5 Infected with Tg/wt 9.9 (i.p) +++ 224
6 Infected with Tg/wt 9.9 (i.p) +++ 252
7 Infected with Tg/wt 9.9 (i.p) + 254
8 Infected with Tg/wt 9.9 (i.p) + 257
9 Infected with Tg/KO (i.c) +++ 210
10 Infected with Tg/KO (i.c) +/2 210
11 TgMHu2ME199K/KO ++ Sac at 240
12 TgMHu2ME199K/wt ++ Sac at 240
13 wt C57Bl/6 2 Sac at 240
14 Mouse RML +++ 180
This table summarizes the results of the transmission experiment as described
in figure 7 b (survival of mice), as well as the presence of PK resistant PrP in
infected samples (panels c &d).
doi:10.1371/journal.ppat.1002350.t003
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mostly pathological markers and in some cases behavioral
changes, but not obvious clinical symptoms, or age dependent
deterioration that correlates with those observed in human
patients [33].
As opposed to models for the more common neurodegenerative
conditions, several genetic prion diseases linked to pathological
mutations in the PRNP gene have been reconstructed clinically in
transgenic mice lines. Each of these models demonstrate several of
the basic features of genetic fatal prion disease, as is the case for
those mimicking GSS linked to the PrP P101L mutation [3] [21],
the D177N CJD or FFI mutations [18,19] or the insertional PrP
modification [34]. These mouse models were seminal in proving
that spontaneous prion disease may indeed result from the
presence of a pathological PrP mutation.
In this work, we describe the properties of a Tg line mimicking
the most common genetic prion disease [3], i.e CJD linked to the
human E200K PrP mutation. Our Tg line presents all prion
relevant properties, spontaneous fatal disease, PrP pathology and
transmission of prion disease to wt mice. This is particularly
intriguing in view of the fact that two other models of this same
mutation failed to generate disease in transgenic mice. While they
may be other explanations for the different results in our case, we
assume that the introduction of the E200K mutation into a
chimeric mouse human PrP, as opposed to a mouse PrP [21] or a
human PrP [20], is of biological importance. Chimeric PrP may
Figure 8. Transmission of TgMHu2ME199K prions to wt mice: pathology. a: Frontal cortex sections of mice infected with RML or with
TgMHu2ME199K prions on a wt or ablated background, analyzed for prion pathological properties, spongiosis, gliosis, and disease related PrP
immunoreactivity with pAb RTC and mAb 6H4. Scale bar in upper left image indicates 50 mm. b: RTC immunoreactivity in the absence of formic acid
for brains infected with TgMHu2ME199K/wt or RML, as well as for naı ¨ve PrP ablated mice. Picture shows different pattern of immunoreactivity for
both infected samples. Scale bar in upper left image indicates 20 mm.
doi:10.1371/journal.ppat.1002350.g008
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in mice. Indeed, chimeric human mouse PrP was required to
transmit at low incubation times genetic and sporadic human
prion disease to mice [15]. Moreover, while Tgs expressing the
GSS 102 mutation in human PrP did not present spontaneous
disease, the same mutation in chimeric PrP did present
neurodegenerative disease [28]. Whether the structure of chimeric
PrP is more favorable for disease transmission or otherwise the
chimeric form has the ability to bind a mouse component
important for transmission of human prion diseases to mouse
models remains to be established.
Another novel feature of our Tg line is the generation of de-
novo infectious prions that could be transmitted to naı ¨ve wt mice.
Indeed, E200K CJD is the genetic disease most similar to the
sporadic forms, in both clinical appearance, age of onset and
pathology [2,10]. This may imply that E200K de-novo prions are
more similar in structure to sporadic ones, which are highly
transmissible [9]. Whether the chimeric background of E200K
PrP in these mice is also a factor in the transmissibility of disease is
unknown at this point, however it is important to state that
chimeric mouse human PrP Tg mice are susceptible for infection
with both mouse and human prions [28].
While the neuropathology features of our Tg mice were similar
to E200K human patients with regard to reduced spongiosis and
intracellular PrP accumulation [24], PK resistant PrP in the
TgMHu2ME199K mice was detected mostly by the C-terminal
pAb RTC, suggesting a considerable fraction of disease related
PrP in the brains of these mice accumulates as a truncated form.
Indeed, diverse truncated PrP forms were also described in brains
of CJD patients [35], including those carrying the E200K
mutation [36]. Interestingly, intraneuronal immunoreactivity in
these CJD patients predominates in the brainstem and may be
associated with alterations in the accumulation of other neurode-
generation-related proteins (e.g. phospho-tau, alpha-synuclein)
[24]. Evaluation of concomitant protein pathology in our model is
the objective of another ongoing study.
Because gCJD is a dominant genetic disorder, we investigated
the properties of the TgMHu2ME199K mice not only on a PrP
ablated but also on a wt PrP background. We first speculated that
the presence of wt PrP may preclude some disease symptoms
related to the absence of the elusive PrP
C activity or to the putative
toxicity of truncated PrP forms, as was shown previously in other
systems [29]. However, this is probably not the case, as can be
inferred from the fact that no significant differences were seen
between both lines of Tg mice in clinical symptoms, kinetics and
pathological examination. Finally, while the investigation of a
small group of homozygous E200K CJD patients showed a
moderate decrease in the age of disease onset for most patients, it
also described a patient with a very slow progressive disease (96
months), who died in the absence of PrP
Sc accumulation [37].
Whether disease onset in one or both lines of TgMHu2ME199K
mice may be modulated by oxidative stress or other pathogenic
insults is under investigation in our laboratory.
In summary, we believe that our TgMHu2ME199K lines will
play a central role both in the elucidation of genetic prion disease
pathogenic mechanism as well as in the search for anti-prion
compounds. The early presence of spontaneous disease followed
by their sequential age related deterioration during several months
until death will permit to study the long term effect of reagents that
may delay disease onset in at risk subjects. Among those to be
tested first are substances suggested to have a marginal but still
encouraging result in already sick CJD patients, such as doxicyline
[38] and flupirtine [7], as well as those believed to present
significant therapeutic results in scrapie infected mice or infected
cells, such as Quinacrine and Simvastatin [39,40]. Novel
approaches such as passive [41] or active immunization, as well
as RNAi inhibition of mutant PrP expression [42], will also be
tested in the near future.
Materials and Methods
Ethical statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Hebrew University Medical school (Permit
Number: MD-11746-5). All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to minimize
suffering.
Generation of TgMHu2ME199K mice
Transgenic mice harboring the E200K mutation were gener-
ated by one of us (ZM) in the Prusiner laboratory as follows. Using
site-directed mutagenesis by PCR, the E200K mutation was
inserted into the chimeric human/mouse PrP open reading frame
(ORF) of an MHu2M construct that was previously prepared as
described [15]. The 0.8 kb SalI-XhoI fragment containing the PrP
ORF with the E200K mutation was inserted into cos.ShaTet and
further injected into transgenic mice ablated for the PrP gene [43].
Creating and screening of the transgenic mice were done as
described [44]. Several lines were produces at the time and at least
2 presented spontaneous prion disease (ZM, personal communi-
cation). For the present project, C57BL/6 female mice were
impregnated with frozen sperm from one of these lines in the
Jackson laboratories. The designated offspring were subsequently
crossed either with wt or with PrP ablated C57BL/6 mice (Harlan
laboratories, obtained by crossing of PrP
0/0 FVB mice [43] with
the C57BL/6 strain for 10 generations, and screened for the
presence of the TgMHu2ME199K PrP, ablated or wt PrP allele,
as required. The mice used in this project are of a mixed C57B/6/
FVB background, ranging from 75- to 95% C57B/6.
Real time PCR
Total RNA from mice brains was isolated using TRI reagent
(Sigma, Israel). cDNA was prepared from 2 mg of total RNA using
MuLV reverse transcriptase and random hexamers (Promega)
according to the manufacturer’s instructions. Quantitative RT-
PCR was carried out in 15 ml reactions containing 1 ml of cDNA,
0.3 mM of the appropriate primers (sigma, Israel), and 7.5 ml of the
SYBR Green master mix (Finnzymes). Gene amplification was
carried out using the GeneAmp 7500 Sequence Detection System
(Applied Biosystems). Measurements were performed in triplicates
and UBC (Ubiquitin C) and TBP (TATA-box binding protein)
transcript levels were used to normalize between samples. The
primers used were PrP, 59-CAA GCA GCA CAC GGT CAC C-
39 (forward), 59-GGC CTG GGA CTC CTT CTG G-39 (reverse)
TBP,5 9-TGT GCA CAG GAG CCA AGA-39 (forward), 59-CCC
CAC CAT GTT CTG GAT-39 (reverse); UBC, 59-CAG CCG
TAT ATC TTC CCA GAC T-39 (forward); 59-CTC AGA GGG
ATG CCA GTA ATC TA-39 (reverse). The primers used for PrP
were chosen so that they can be used for both wt (mouse) PrP as
well as for MHu2M PrP.
Spontaneous disease in the TgMHu2ME199K mice
Mutant TgMHu2ME199K mice from both lines (PrP ablated
or wt background) were followed twice a week for the appearance
of spontaneous neurological disease. Mice were scored for disease
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described in Table 2. This scale was designed by us to fit the
clinical symptoms observed in the Tg mice and was proven to be
parallel to the NNS (neurological severity score). Mice were
sacrificed according to the ethical requirements of the Hebrew
University Animal authorities (when too sick or paralyzed to reach
food and water, or after loosing 20% body weight).
Clinical and behavioral evaluation
As described in table 2 mice were scored for disease severity and
progression according to a scale of clinical signs designed by us to
fit the clinical symptoms observed in the Tg mice. Hind limbs
weakness was first evaluated by closely watching the mouse
walking on a flat surface looking for sings of abnormal limb
posture or abnormal walking pattern (high or low gait, leg
dragging). Next, mice were tested for their ability to walk on a
3 cm beam in a straight line and maintain balance. Finally mice
were lifted by their tail to check for leg clasping. Full paralysis was
evaluated by total lack of movement in the limb. This scale of
scoring was proven to be parallel to the NSS (neurological severity
score) [45]. Blindness was tested by the lack of reaction of the mice
to a paper slowly placed before its eyes.
Transmission of disease from TgMHu2ME199K mice to wt
mice
10% brain homogenates of asymptomatic or sick TgMHu2-
ME199K/wt, sick TgMHu2ME199K/ko, as well as from control
TgMHu2M and naı ¨ve wt mice were each inoculated i.p. or i.c, as
designated in the text, into a group of 6 C57BL/6 mice (Harlan
laboratories). The inoculated mice were scored twice a week for
clinical signs of prion disease until the beginning of symptoms and
more closely thereafter. Following termination of each experiment,
mice were sacrificed and analyzed for pathology and for the
presence of disease related PrP.
Pathology
Four mm thick sections of formalin fixed, paraffin embedded
brains of TgMHu2ME199K mice as well as of C57BL/6 mice
infected with TgMHu2ME199K brains, in addition to controls
and PrP ablated mice were evaluated for the presence of disease
related PrP, gliosis and spongiform changes as previously
described [24]. A less harsh epitope retrieval method, with the
avoidance of formic acid, was also applied in some cases.
Immunoblotting of brain homogenates from
TgMHu2ME199K mice
Brains from TgMHu2ME199K mice on a wt or ablated
background, normal mice, control TgMHu2M and scrapie RML
infected mice were homogenate at 10% (W/V) in 10 mM Tris-
HCl, pH 7.4 and 0.3 M sucrose. For Proteinase K digestions,
30 ml of 10% brain homogenates extracted with 2% sarkosyl were
incubated with 30 mg/ml Proteinase K for 30 min at 37uC.
Samples were subsequently subjected to SDS PAGE and
immunoblotted with the diverse a-PrP antibodies, as described
in Figure 2 a. Protein precipitation experiments, as the ones
observed in Figure 5 c, were performed by ultracentrifugation of
Sarkosyl extracted homogenates at 100000 g, and subsequently
separating pellets from supernatant. Deglycosylation by PNGase
was performed as previously described [46].
Sucrose gradient centrifugation experiments
Normal and prion infected Sarkosyl extracted brain homoge-
nates were subjected to sucrose gradients as described [47].
Shortly, 140 ml of 10% brain homogenates extracted in the
presence of 2% Sarkosyl were overlaid on a sucrose gradient
composed of layers of increasing concentrations of sucrose (10–
60%). Gradients were then centrifuged for 1 h at 55000 rpm in a
Sorval mini-ultracentrifuge and subsequently 11 samples of 120 ml
were collected from the top to the bottom. Gradient fractions were
then immunoblotted with either a PrP pAb RTC or RVC.
Accession numbers
1. prnp mus musculus: ENSMUST00000091288
2. prnp homo sapiens: ENSG00000171867
3. UBC mus musculus: ENSMUSG00000008348
4. TBP mus musculus: ENSMUSG00000014767
Supporting Information
Figure S1 Time course histopathology and PrP immu-
noreactivity in the brain and spinal cord of TgMHu2-
ME199K mice. a: Hematoxylin & Eosin (H&E) staining of
frontal cortex: Spongiform change was noted only focally in end-
stage animals (H&E staining, frontal cortex). b–d: GFAP staining:
Reactive astrogliosis progressed with the age of the animals as
represented here in the frontal cortex (b), thalamus (c), and the
spinal cord (d). e & f: PrP immunoreactivity. PrP immunoreac-
tivity at disease end point is presented with 2 a PrP antibodies,
pAb RTC and mAb 6H4, in different brain areas. For comparison
the right lower image is a representative micrograph of
intraneuronal PrP immunoreactivity in the putamen in human
genetic CJD associated with E200K mutation using aPrP mAb
12F10. Bar in upper left image represents 50 mm for all upper
panel images and 20 mm for lower panel images.
(TIF)
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